MIRZOTAMAB CLEZUTOCLAX
UNII TY49T0B03B

Substance Identification & Data

This profile provides standardized clinical and technical data for Mirzotamab Clezutoclax, uniquely identified by the FDA Unique Ingredient Identifier (UNII) TY49T0B03B.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2229859-12-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

TY49T0B03B

CAS Registry Number

2229859-12-3

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

MIRZOTAMAB CLEZUTOCLAX

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C157279

National Cancer Institute reference terminology for clinical and research data.

INN ID

11147

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

JK-93

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Mirzotamab Clezutoclax. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

MIRZOTAMAB CLEZUTOCLAX

Common Names & Synonyms

IMMUNOGLOBULIN G1 (234-ALANINE,235-ALANINE), ANTI-(HUMAN B7 HOMOLOG 3 PROTEIN) (HUMAN MONOCLONAL PR-1651850 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL PR-1651850 .KAPPA.-CHAIN, DIMER, BIS(THIOETHER) WITH 2,6-ANHYDRO-8-(2-(((((2-((3-((4-(6-(8-((2-BENZOTHIAZOLYLAMINO)CARBONYL)-3,4-DIHYDRO-2(1H)-ISOQUINOLINYL)-2-CARBOXY-3-PYRIDINYL)-5-METHYL-1H-PYRAZOL-1-YL)METHYL)-5,7-DIMETHYLTRICYCLO(3.3.1.13,7)DEC-1-YL)OXY)ETHYL)((3S)-3,4-DIHYDROXYBUTYL)AMINO)CARBONYL)OXY)METHYL)-5-((N-(2-((3S,5S)-3-((3-CARBOXY-2-MERCAPTO-1-OXOPROPYL)AMINO)-2-OXO-5-((2-SULFOETHOXY)METHYL)-1-PYRROLIDINYL)ACETYL)-L-VALYL-L-ALANYL)AMINO)PHENYL)-7,8-DIDEOXY-L-GLYCERO-L-GULO-OCTONIC ACID

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD276 ANTIGEN (4IG-B7-H3, B7 HOMOLOG 3, COSTIMULATORY MOLECULE)), MONOCLONAL ANTIBODY, CONJUGATED WITH CLEZUTOCLAX, AN INHIBITOR OF BCL-2-LIKE PROTEIN 1 (BCL2-L-1, APOPTOSIS REGULATOR BCL-X); .GAMMA.1 HEAVY CHAIN CHIMERIC(1-446) (VH (MUS MUSCULUS IGHV3-1*02 (87%) (IGHD)-IGHJ2*01 (87%)/HOMO SAPIENS IGHV4-38-2*01 (84%) (IGHD)-IGHJ4*01 (87%)) (9.7.9) (1-116)-HOMO SAPIENS IGHG1*03 (CH1(R97>K(213))),CH2(L4 >A(233),L5 >A(234))) (117-446)) (219-214')-DISULFIDE WITH .KAPPA. LIGHT CHAIN HUMANIZED(1'-214') (V-KAPPA (HOMO SAPIENS IGKV1-39*01 (82%) IGKJ2*02) (6.3.9) (1'-107')-HOMO SAPIENS IGKC*01 (108'-214')), DIMER (225-225'':228-228'')-BISDISULFIDE, PRODUCED IN CHO CELLS, GLYCOFORM ALFA; CONJUGATED,ON AN AVERAGE OF 2 CYSTEINYL, WITH CLEZUTOCLAX, COMPRISING A CLEAVABLE DIPEPTIDE (VALINE-ALANINE) LINKER

MIRZOTAMAB CLEZUTOCLAX [INN]

MIRZOTAMAB CLEZUTOCLAX [USAN]

MIRZOTAMAB CLEZUTOCLAX [WHO-DD]